Domainex, a contract research organization, announced a collaboration with Sigma-Aldrich to advance the study of epigenetic proteins involved in cancer and stem cell biology. Through the collaboration, Domainex will use its protein expression technology to produce domains of epigenetic proteins to develop biochemical assays, while Sigma-Aldrich will use the proteins to develop monoclonal antibodies. These tools will help researchers study the function of these important proteins. Funding from the UK Technology Strategy Board will support the work.